Anand Patel, MD, shares primary efficacy results from a phase 2 study evaluating a TKI plus inotuzumab ozogamicin–based therapy in newly diagnosed Ph-positive ALL.
Anand Patel, MD
Advertisement
Anand Patel, MD, is an assistant professor of medicine and medical director of Inpatient Leukemia Service at the University of Chicago Medicine.
Articles by Anand Patel, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Sacituzumab Govitecan Monotherapy and In Combination With Pembrolizumab in Frontline TNBC
2
Dr Tolaney on the FDA Approval of First-Line Sacituzumab Govitecan Plus Pembrolizumab for TNBC
3
Dr Morgans on the Design of the ARACOG Trial in Prostate Cancer
4
Daratumumab Retreatment Displays Activity in Relapsed Myeloma Following Continuous Frontline Therapy
5